Our #SITC25 recap is out today! Check out the standout presentations and insights from top institutions and speakers: bit.ly/3LLunuM.

Show Post

Thanks to our readers who dive into it all — from experimental immunotherapy to cancer immunobiology to innovative methods 💙 You prove that science is stronger when we stay curious, stay current, and stay connected. #CancerCure #ResearchMatters

Show Post

For those who couldn't attend the new #AACRIO25 meeting, check out our digest here 👉 bit.ly/3XvBUkp. We included talks from @jimallisonphd.bsky.social, @danielathommen.bsky.social, @jcstark.bsky.social and more! (1/2)

Show Post

While checkpoint blockade is currently used in roughly half of patients with cancer, tumors often resist treatment or evade detection, limiting responses. Read a summary of Stark's talk here 👉 bit.ly/3XvBUkp  @mitofficial.bsky.social @jcstark.bsky.social

Show Post

Ressler et al. reported the safety and efficacy of a single-arm, phase II, neoadjuvant, two-stage clinical trial of T-VEC in cutaneous BCC, which was preliminarily stopped for early success after the first stage. bit.ly/3EjaTdi #ClinicalTrial #Immunotherapy

Show Post